Clinical Trial Results:
The effect of chlorpromazine (Largactil), a dopamine type 2-(D2-) receptor antagonist, on esophageal sensitivity in healthy volunteers: a randomized, double-blind, placebo-controlled study
Summary
|
|
EudraCT number |
2016-003131-38 |
Trial protocol |
BE |
Global end of trial date |
19 Oct 2017
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Feb 2021
|
First version publication date |
07 Feb 2021
|
Other versions |
|
Summary report(s) |
Thesis manuscript |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
DOPA2016
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
TARGID
|
||
Sponsor organisation address |
Herestraat 49, Leuven, Belgium, 3000
|
||
Public contact |
TARGID, TARGID, KU Leuven, 32 16344225, jan.tack@kuleuven.be
|
||
Scientific contact |
TARGID, TARGID, KU Leuven, 32 16344225, jan.tack@kuleuven.be
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
20 Nov 2017
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
01 Jun 2017
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
19 Oct 2017
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To investigate the effect of chlorpromazine (Largactil) on esophageal sensitivity in healthy subjects
|
||
Protection of trial subjects |
Identification of trial subjects was protected by the implementation of subject numbers
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Jun 2017
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 13
|
||
Worldwide total number of subjects |
13
|
||
EEA total number of subjects |
13
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
13
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||
Recruitment
|
||||||||||
Recruitment details |
- | |||||||||
Pre-assignment
|
||||||||||
Screening details |
Healthy volunteers were recruited for this study. | |||||||||
Period 1
|
||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||
Is this the baseline period? |
Yes | |||||||||
Allocation method |
Randomised - controlled
|
|||||||||
Blinding used |
Double blind | |||||||||
Roles blinded |
Subject, Investigator | |||||||||
Arms
|
||||||||||
Are arms mutually exclusive |
No
|
|||||||||
Arm title
|
Chlorpromazine | |||||||||
Arm description |
- | |||||||||
Arm type |
Experimental | |||||||||
Investigational medicinal product name |
Chlorpromazine
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||
Routes of administration |
Intravenous use
|
|||||||||
Dosage and administration details |
Ten mg chlorpromazine for IV infusion was added to 100mL NaCl 0.9%, infusion ran over 30 minutes.
|
|||||||||
Arm title
|
Placebo | |||||||||
Arm description |
- | |||||||||
Arm type |
Placebo | |||||||||
Investigational medicinal product name |
Saline solution
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||
Routes of administration |
Intravenous use
|
|||||||||
Dosage and administration details |
100mL NaCl 0.9%, infusion ran over 30 minutes.
|
|||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial (overall period)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Chlorpromazine
|
||
Reporting group description |
- | ||
Reporting group title |
Placebo
|
||
Reporting group description |
- |
|
|||||||||||||
End point title |
Change in mechanical stimulation | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Between the two conditions
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Paired t test for mechnical stimulation | ||||||||||||
Comparison groups |
Chlorpromazine v Placebo
|
||||||||||||
Number of subjects included in analysis |
26
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
= 0.53 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Confidence interval |
|
|||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||
Timeframe for reporting adverse events |
From signing the informed consent until the end of the last study visit.
|
||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||
Dictionary version |
23
|
||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||
Reporting group title |
Chlorpromazine
|
||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||
|
|||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |